Epithelial cell-cell contacts maintain normal glandular tissue homeostasis and their breakage can trigger epithelial-to-mesenchymal transition (EMT), a fundamental step in the development of metastatic cancer. Despite the ability of C-type lectin domains (CTLDs) to modulate cell-cell adhesion it is not known if they modulate epithelial adhesion in EMT and tumor progression. Here the multi-CTLD mannose receptor, Endo180 (MRC2/uPARAP), was shown using Kaplan-Meier analysis to be predictive of survival outcome in men with early prostate cancer. A proteomic screen of novel interaction partners with the fourth CTLD (CTLD4) in Endo180 revealed that its complex with CD147 is indispensable for the stability of three-dimensional (3D) acini formed by non-transformed prostate epithelial cells (PECs). Mechanistic study using knockdown of Endo180 or CD147, and treatment with an Endo180 monoclonal antibody (mAb) targeting CTLD4 (clone 39.10), or a dominant-negative GST-CTLD4 chimeric protein, induced scattering of PECs associated with internalization of Endo180 into endosomes, loss of E-cadherin (CDH1/ECAD) and unzipping of cell-cell junctions. These findings are the first to demonstrate that a CTLD acts as a suppressor and regulatory switch for EMT; thus, positing that stabilization of Endo180-CD147 complex is a viable therapeutic strategy to improve rates of prostate cancer survival.
Introduction

Epithelial-to-mesenchymal transition (EMT) is a reversible trans-differentiation
program involving a switch from the apical-to-basal polarization of epithelial cells, that are adherent to each other and the basement membrane, to a detached mesenchymal-like phenotype that is highly motile and invasive (1) . EMT is defined according to its different biological contexts, including: normal embryonic development (Type I EMT); wound healing, tissue regeneration and organ fibrosis (Type II EMT); or tumor progression (Type III EMT) (2) . EMT has also been closely linked to the early stages of tumor development, following the finding that EMT-associated metastatic dissemination precedes detectable adenocarcinoma formation in glandular tissue (3) . This strongly suggests that molecular triggers of EMT in normal epithelial layers should be prioritized as targets for the development of therapeutics that can prevent metastasis and improve cancer survival rates.
C-type lectin domains (CTLDs) facilitate the Ca 2+ -dependent interaction of cell surface receptors with carbohydrate moieties, playing critical roles in the innate immune response to pathogens, glycoprotein turnover and modulation of cell-matrix and cell-cell interactions (4) . In a biomarker study we have previously revealed that the multi-CTLD receptor Endo180 (CD280, CLEC13E, KIAA0709, MRC2, TEM9, uPARAP) is highly expressed in cells with an EMT-like phenotype and correlated with Gleason score in prostate cancer (5) . In the same study, Endo180 expression was observed in epithelial cells lining the ducts of glandular tissue affected by benign prostatic hyperplasia (BPH) or low-grade prostate cancer (5) . Given that Endo180 expression and subcellular localization in constitutively recycling endosomes in mesenchymal-like tumor cells promotes extracellular matrix (ECM) remodelling (6) (7) (8) (9) (10) , disassembly of cell-cell and cell-matrix adhesions and cell motility (11, 12) , and enhanced tumor growth (7), we hypothesized that these pro-EMT properties are negatively regulated in normal prostate epithelial cells
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C-type lectin domain acts as tumor suppressor 4 (PECs). In accordance, this study has identified a novel EMT-suppressor complex between the fourth of eight CTLDs, CTLD4, in Endo180 and the cell adhesion modulator CD147 that is indispensible for PEC stability. We suggest that disruption of the suppressive Endo180-CD147 complex contributes to the marked decrease in survival attributed to Endo180 expression in low-to-intermediate grade (Gleason 5-7 score) prostate cancer. Hence, stabilization of the interaction between CTLD4 in Endo180 and CD147 is a promising therapeutic strategy that could suppress EMT and metastatic dissemination at the early stages of prostate adenocarcinoma formation.
Materials and Methods
Immunohistochemical analysis
The tissue biopsies on the NCLPC1 and NCLPC4 prostate cancer tissue microarrays (TMAs) used in this study were obtained with consent and approved by the scoring approach (two independent scorers) was used to calculate the % of acini containing ≥4 cells for each condition relative to the control (set at 100%).
Immunoblotting and immunofluorescent staining
Immunoblotting and immunofluorescent staining of monolayers and 3D cultures were carried out with primary antibodies (see Supplementary Table S1 ); and appropriate HRP-conjugated or Alexa®Fluor-conjugated secondary antibodies (8, 11, 12, 14 immunoprecipitated from whole cell lysates using a FLAG-tagged protein immunoprecipitation kit (#FLAGIPT1; Sigma-Aldrich). Pulled down and immunopreciptated proteins were resolved using SDS-PAGE and immunoblotted (see above).
Statistics
SPSS (Version 19) was used to create Kaplan Meier plots (censored to account for any patient withdrawals before the final outcome is observed) and to perform Log Rank, Breslow and Tarone-Ware analyses and Student's t-tests (two tails, α = 0.05).
Results
Endo180 expression in early prostate neoplasms decreases survival
Endo180 was analyzed for its contribution to clinical outcome using prostate cancer
TMAs that were established at the University of Newcastle. In accordance with our earlier findings using a commercial TMA (5) , which suggests that Endo180-dependent stabilization of cell-cell adhesions is a molecular mechanism that is exclusive to non-transformed prostatic epithelia. Endo180 siRNA oligonucleotides #1 and #2 respectively bind to the 3' UTR noncoding and mRNA coding regions of the gene ( Fig. 2A) , therefore oligonucleotide #1 is not able to silence ectopically expressed Endo180-Flag (Fig. 2B) . We used this distinguishing feature of these two oligonucleotides to determine if ectopic expression of Endo180 during endogenous receptor silencing can reverse this dramatic change in acinar architecture. Moreover, Endo180-Flag was clearly localized to the basolateral membrane of PECs treated with Endo180 siRNA oligonucleotide #1 (Fig. 2C ). This data establishes that loss of Endo180 from the plasma membrane in epithelial cell monolayers may be a driving force behind the switch to an EMT-like phenotype and the dissemination of cells into the surrounding matrix.
CTLD4 in Endo180 receptor modulates glandular epithelial cell-cell adhesion
Differential staining patterns for Endo180 with different mAbs indicated that two subcellular pools of the receptor are present in PEC acini. The first subcellular pool of Endo180 is localized at the basolateral membrane and recognized by A5/158 mAb;
whereas the second is localized in endosomes and recognized by 39.10 mAb (Fig. 3A) .
Treatment with the two antibodies revealed that incubation with 39.10 mAb, but not A5/158, resulted in the same effect as Endo180 silencing by scattering PECs into the surrounding rBM (Fig. 3B) . Epitope mapping has confirmed that A5/158 mAb binds to CTLD2 in Endo180 (11) . Using a similar epitope mapping approach that involved immunoblot analysis of truncated forms of Endo180 with successive deletions in each of its domains down to CTLD5, it was confirmed that 39.10 mAb binds to CTLD4
( Supplementary Figs. S3A and B) . This indicates that CTLD4, but not CTLD2, is required for PEC adhesion. The inability of 39.10 mAb to promote cell scattering from 3D
aggregates formed by metastatic PTCs (Supplementary Fig. S4 ) is likely to be the result of constitutive recycling of the receptor from the plasma membrane and its localization to endosomes in transformed mesenchymal-like cells (Fig. 3C ) (11, 12) .
The strong localization of Endo180 observed at the basolateral membrane of untreated or mouse IgG treated PEC monolayers was lost following treatment with 39.10 mAb, but not A5/158 mAb, resulting in most of the receptor being localized to endosomes (Fig. 3C ). In line with the induction of programmed EMT, the treatment of PECs with 39.10 mAb resulted in a decrease in total cellular levels of E-cadherin (0.3-fold) and β-catenin (0.7-fold) (Fig. 3D) . In contrast, levels of these core cell-cell adhesion components were unaffected by treatment with A5/158 mAb (E-cadherin: 0.9-fold; β-catenin: 0.9-fold) or IgG control (E-cadherin: 0.8-fold; β-catenin: 1.0-fold) (Fig. 3D) . Again the disseminated PECs retained their ability to survive, as confirmed by the lack of effect of 39.10 mAb on their cell cycle and viability (Supplementary Figs. S2D-G) .
We next considered the hypothesis that the inability of 39.10 mAb to recognize Endo180 localized at the plasma membrane is due to CTLD4 epitope being masked by unknown interaction partner(s). We also predicted that treatment with soluble GST-CTLD4
would disrupt epithelial cell-cell contacts by imposing a dominant negative effect on the unknown interaction partner(s) (Fig. 4A) . To test this hypothesis we generated GST-CTLD2 and GST-CTLD4 chimeric proteins (Fig. 4B ) and used them as competing agents
antibody blocking experiments, GST-CTLD4, but not GST-CTLD2, induced scattering of RWPE-1 and BPH-1 cells into the surrounding rBM (Fig. 4C ) without affecting cell viability (Supplementary Figs. S2H ).
CTLD4 in Endo180 receptor interacts with highly glycosylated CD147
Proteomic analysis of interaction partners eluted from GST-CTLD4-conjugated sepharose beads that had been incubated with PEC whole cell lysates revealed that Endo180 forms a molecular complex with CD147 and CD36 ( Fig. 4D and E) . Given that CD147 is associated with prostate cancer progression (16) we decided to explore its cooperative role with Endo180. Endo180-CTLD4 and CD147 complex formation was further demonstrated by the ability of GST-CTLD4, but not GST-CTLD2 or GST alone, to bind to the highly glycosylated and active form of CD147 ( Supplementary Fig. S5A ). Anti-
Flag immunoprecipitation of highly glycosylated CD147 from PECs transfected with
Endo180-Flag also consolidated its interaction with Endo180 ( Supplementary Fig. S5B ).
Conversely, E-cadherin, β-catenin and ZO-1 were not detected in Endo180-Flag immunoprecipitates ( Supplementary Fig. S5C ), suggesting that Endo180 is not incorporated into adherens and tight junction protein complexes. This is not surprising given that Endo180 is weakly localized in lateral cell-cell junctions and strongly localized at the basal plasma membrane of PEC acini (Fig. 3A) . In agreement, E-cadherin and β-catenin were not identified as Endo180 interaction partners ( Supplementary Fig. S5C ).
Endo180-CD147 complex disassembly promotes EMT
Glycosylation of CD147, following its disassociation from caveolin-1, promotes its self-aggregation, stabilization at the plasma membrane and enhanced cell adhesion (17) .
Based on the ability of highly glycosylated CD147 localized at the plasma membrane to promote cell adhesion, we determined whether its interaction with CTLD4 in Endo180 was responsible for cell-cell adhesion stability in PEC acini. Incubation of PECs with increasing concentrations of the dominant negative GST-CTLD4 construct decreased the ratio of high/low glycosylated CD147 present in whole cell lysates (2 µg/ml: ratio = 0.71; 4 µg/ml: ratio = 0.25) compared to untreated cells (ratio = 1.0) or cells treated with GST alone (ratio = 1.16) as determined by semi-quantitative immunoblot analysis (Fig. 5A) . The same treatment did not induce any change in the glycosylation status of CD147 in PTC's (Fig.   5A ). Similar to treatment with GST-CTLD4, treatment with 39.10 mAb also decreased the ratio of high/low glycosylated CD147 in PECs (control IgG treatment: ratio = 1.85; 39.10 mAb treatment: ratio = 0.16) but not PTCs (Fig. 5B) . The shift in the glycosylation status of CD147 -from high to low -induced by GST-CTLD4 in PECs correlated CD147 internalization (Fig. 5C , arrowheads) and unzipping of adherens junctions (Fig. 5C , arrows). These results consolidate the link between Endo180-CD147 complex disruption and the initiation of EMT in prostate epithelial monolayers.
To shed more light on our newly established model of Endo180-CD147 dependent cell-cell adhesion and EMT suppression we costained PEC acini with anti-CD147 and A5/158 or 39.10 mAbs. The findings revealed that CD147 localizes with Endo180 at the basal plasma membrane but not in endosomes (Fig. 6A) . Finally, we demonstrated that CD147 silencing (Fig. 6B ) also scattered PECs into their surrounding rBM (Fig. 6C) , which is in agreement with the pro-EMT effect observed following their treatment with Endo180 siRNA oligonucleotides ( Supplementary Fig. S1B ) 39.10 mAb (Fig. 3B ) and GST-CTLD4 (Fig. 4C ).
Discussion
The revelation that Endo180 interacts with, and stabilizes, highly glycosylated CD147 at the plasma membrane of normal PECs, and that destabilization of the complex Rodriguez-Teja et al.
C-type lectin domain acts as tumor suppressor 13 leads to Type III EMT, establishes a new type of molecular trigger for the development of invasive prostate cancer. The findings of this study also confirm that, similar to the upregulation of CD147 (5, 16) , the increased expression of Endo180 is correlated with increasing Gleason score (Fig. 1B) and has prognostic value as an independent predictor of overall survival (Fig. 1C) . Although previous work has suggested that there is a close association between Endo180 expression and an EMT-like phenotype in transformed cells derived from breast (7), pancreatic (10) and prostate (5) cancer the divergent mechanistic roles of Endo180 in this fundamental process had not been appreciated. Endo180 and CD147 have both been correlated with low levels of E-cadherin in tumor tissue and both are under the transcriptional regulation of the core EMT trigger transforming growth factor-beta (TGF-β) (7, 8, 19, 20) . In an aligned study we have demonstrated that the stiff microenvironment role with CD36 (see Fig. 4D ) and other glycosylated ligands and bona fide lectin activity in addition to its exploitation as a therapeutic target in metastatic cancer.
The importance of CTLD4 for the formation of the suppressive Endo180-CD147 complex in PECs was not uncovered in Endo180 ΔEx2-6/ΔEx2-6 mice that express a truncated form of the Endo180 receptor, including an intact CTLD4, and reach adulthood (31, 32) .
Nevertheless, our analysis of prostate tissue from adult Endo180 ΔEx2-6/ΔEx2-6 mice has revealed that a significant architectural change occurs that closely recapitulates prostatic intraepithelial neoplasia (PIN), a common precursor for invasive prostate cancer migrate via ligand-specific chemotactic mechanisms towards distant sites (11, 12) (Fig. 7) .
It is also plausible that CD147 and endosomal Endo180 help to coordinate ECM turnover via their respective activation of MMPs (36) and participation in collagen remodeling (7, 8, 14, 33) . In addition to inducing Endo180 internalization, Endo180-CTLD4 and CD147 complex disruption deglycosylates and internalizes CD147. Hence, it is possible that Endo180 stabilizes CD147 at the plasma membrane by competing with its negative regulator caveolin-1 (17) .
Progression towards metastatic castrate resistant prostate cancer and the contribution of aberrant androgen signaling to this process remains a major therapeutic challenge (37) . Negative androgen receptor (AR) status is correlated with the expression of Endo180 in breast cancer (7) . This suggests that dysregulation of the androgen axis and AR signaling may act as a trigger for Endo180 expression and enhanced metastatic potential. A putative role for Endo180 in androgen-independent prostate cancer is further consolidated by its absence from the androgen-dependent and non-invasive LNCaP prostate cancer cell line (8) . Together these observations set a precedent for investigating the interaction between AR signaling and the Endo180 axis.
In combination with the continued validation of soluble Endo180 in serum as a highly sensitive and specific biomarker for metastatic disease (38) ; the findings of this study suggest that strategies for anti-metastatic therapy should: (a) promote stabilization of the suppressive complex between CTLD4 in Endo180 and CD147 at the plasma membrane, in the case of indolent diseases like BPH; and (b) exclusively target endosomal Endo180, in the case of aggressive tumors. We predict that the aligned introduction of Endo180 as a prognostic marker and therapeutic target will have a significant impact on the prognosis and prevention of metastasis in prostate cancer and could also be of benefit in the management of other types of carcinoma. 17 comments during manuscript preparation. This paper is dedicated to Peter Gannaway, a good friend, who passed away aged 74 years in December 2012 due to advanced prostate cancer. (high/low glycosylated forms indicated) and GAPDH levels in RWPE-1 and PC3 whole cell
